Armistice Capital LLC Acquires 484,000 Shares of Intellia Therapeutics, Inc. $NTLA

Armistice Capital LLC raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 72.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,156,000 shares of the company’s stock after acquiring an additional 484,000 shares during the quarter. Armistice Capital LLC owned approximately 1.00% of Intellia Therapeutics worth $10,392,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. AQR Capital Management LLC raised its holdings in Intellia Therapeutics by 154.1% during the first quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after acquiring an additional 55,118 shares in the last quarter. Woodline Partners LP bought a new stake in Intellia Therapeutics during the first quarter worth about $171,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Intellia Therapeutics by 8.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after acquiring an additional 38,521 shares in the last quarter. Creative Planning raised its holdings in Intellia Therapeutics by 12.9% during the second quarter. Creative Planning now owns 33,102 shares of the company’s stock worth $310,000 after acquiring an additional 3,795 shares in the last quarter. Finally, Cetera Investment Advisers raised its holdings in Intellia Therapeutics by 47.4% during the second quarter. Cetera Investment Advisers now owns 33,532 shares of the company’s stock worth $315,000 after acquiring an additional 10,785 shares in the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Stock Up 4.5%

NASDAQ:NTLA opened at $15.20 on Thursday. The stock’s 50 day moving average price is $13.70 and its two-hundred day moving average price is $12.46. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -4.29 and a beta of 1.92. Intellia Therapeutics, Inc. has a 12-month low of $7.95 and a 12-month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. The firm had revenue of $15.05 million for the quarter, compared to analyst estimates of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter in the prior year, the company earned ($1.10) earnings per share. Equities research analysts expect that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wells Fargo & Company upped their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. Truist Financial upgraded Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Wall Street Zen lowered Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. New Street Research set a $25.00 target price on Intellia Therapeutics in a report on Monday. Finally, Bank of America reiterated a “neutral” rating on shares of Intellia Therapeutics in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $20.46.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.